Zai Lab Signs a Development and Commercialization Agreement with Regeneron for REGN1979 in Oncology

Zai Lab Signs a Development and Commercialization Agreement with Regeneron for REGN1979 in Oncology

Shots:

  • Regeneron to receive $30M up front and ~$160M as regulatory and commercial milestones. Zai Lab will lead the global development costs of REGN1979 and will receive exclusive rights to develop and commercialize REGN1979 to treat oncology in China, Hong Kong, Taiwan and Macau
  •  The alliance will support the global clinical development of REGN1979, initiating with ongoing P-II study in B-NHL. If the therapy approved, Zai Lab will leverage its capabilities to commercialize REGN1979 in these regions, while Regeneron will manufacture & supply the therapy
  •  REGN1979 is a CD20xCD3 bispecific antibody, currently being evaluated in P-I study for late stages of FL, DLBCL and other lymphomas and registrational P-II study and has received the US FDA’s BT designation for FL & DLBCL

Click here ­to­ read full press release/ article | Ref: Zailab | Image: Business Wire